Pfizer Inc.

Recent Events

News & Analysis

patent and pfizer inc. - All News and Analysis

• Actavis launches challenge to Pfizer drug

  Financial Times - 2009-10-01

  Actavis, the Iceland-based generic company, yesterday launched the most high profile commercial challenge in western Europe to Pfizer's best-selling and patentprotected medicine.The company said it had made a first shipment of 30m tablets into Spain of a cheaper variant of Lipitor, known generically as atorvastatin, which is widely prescribed...

  Tags: Spain, Patent, Pfizer Inc., Actavis, Company News, General News, Health & Healthcare, Marketing, New Products & Services, Financial Times

• Pfizer to Close S.F. Biotech Center in Favor of Unit Accused in Patent Suit

  BNET - 2009-07-07

  Pfizer is pulling out of its much-heralded Biotherapeutics and Bioinnovation Center in San Francisco. The BBC is no longer relevant now that Pfizer has acquired Wyeth's big biotech assets. by Jim Edwards

  Tags: Patent, Pfizer Inc., Biotechnology, Asset Management, Operational Planning, Business Operations, Jim Edwards

• Pfizer Patent Suit Could Make Elan Bapineuzamab Talks Go a Whole Lot Easier

  BNET - 2009-07-06

  Could a patent infringement case filed against Pfizer just before the holiday help Elan CEO Kelly Martin in his negotiations with Wyeth over revenues from bapineuzamab, his Alzheimer's drug? The commercialization of bapi will be "complicated," Martin said, given Johnson & Johnson's recent deal for a stake in them and...

  Tags: Wyeth, Patent, Pfizer Inc., Free Trade, Finance, Jim Edwards

• Pfizer-Wyeth: Credit Markets Have Doubts About the Deal; Patent Cliff Problem NOT Solved

  BNET - 2009-01-27

  Some housekeeping notes on the Pfizer-Wyeth merger: The patent cliff remains unfilled, the WSJ reports: ... between 2010 and 2015, the combined company's revenues will drop by $11 billion to $62 billion. Health-care analysis firm Datamonitor estimates that products accounting for 38.5% of Pfizer's 2007 sales will...

  Tags: Wyeth, Patent, Pfizer Inc., Sales Strategy, Taxes, Research & Development, Operational Accounting, Free Trade, Sales Force Management, Personal Finance, Sales, Financial Planning, Finance, Business Operations, Jim Edwards

• Pharma Roundup: Pfizer's Lipitor Patent, Wyeth and Crucell, and More

  BNET - 2009-01-07

  Court re-validates Pfizer's Lipitor patent; Wyeth wants to buy Crucell; new spin-off Facet cuts jobs; Merckle family to sell Ratiopharm. by John Maas

  Tags: Wyeth, Patent, Pfizer Inc., Crucell, John Maas

• Pharma Roundup: Pfizer's Market Share, Sanofi's Patent, and More

  BNET - 2008-11-07

  GSK and Roche to overtake Pfizer by 2012? Also: Canadian patent ruling helps Sanofi, Daiichi Sankyo completes Ranbaxy purchase. by John Maas

  Tags: Patent, Pfizer Inc., John Maas, Roche Holding AG, Sanofi

• Pharma Roundup: Sanofi and Pfizer Trim Obesity Drugs, Teva Challenges Merck Patent, and More

  BNET - 2008-11-06

  Sanofi, Pfizer cancel obesity drugs; Merck faces patent challenge from Teva; Medco CEO predicts 2009 legislation on biotech generics; contract research organizations hurting, too. by John Maas

  Tags: Patent, Pfizer Inc., Merck & Co. Inc., Biotechnology, John Maas

• Pfizer Cuts a Deal -- No Bid for Ranbaxy

  BNET - 2008-06-18

  So Pfizer apparently won't be playing the spoiler in the Daiichi-Ranbaxy merger after all. Instead, CEO Jeff Kindler cut a deal with the Indian generics maker that will delay the introduction of generic Lipitor by about 20 months. Ranbaxy is now spared the cost and uncertainty involved...

  Tags: Patent, Pfizer Inc., Agreement, Ranbaxy, Lipitor, David P. Hamilton

• U.S. Patent and Trademark Office to Confirm Patentability of Lipitor Basic Patent

  - 2008-04-30

  NEW YORK -- Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued a communication notifying the company that it will confirm the patentability of the claims of Pfizer's '893 basic patent for Lipitor. The Patent Office had conducted a re-examination of the '893 patent in response...

  Tags: Lipitor, patent, Pfizer Inc., U.S. Patent and Trademark Office

• Federal Court in Canada Upholds Pfizer's Norvasc Patent; Decision Prevents Launch of Generic Amlodipine Besylate Product by Pharmascience until 2010

  - 2008-04-17

  NEW YORK -- Pfizer Inc said today that the Canadian Federal Court has upheld a Pfizer patent covering amlodipine besylate, the active ingredient in Norvasc. The court issued an order prohibiting regulatory approval of Pharmascience's proposed product in Canada until Pfizer's amlodipine besylate patent - Canadian Patent No. 1,321,393 -...

  Tags: patent, Pfizer Inc.